- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.10. | Alkermes plots $2.1B acquisition of Avadel and its long-acting narcolepsy drug Lumryz | ||
| 22.10. | Consolidating Novavax transfers Maryland HQ lease to AstraZeneca in $60M deal | ||
| 22.10. | Real Chemistry debuts AI tool to stay on top of FDA's torrent of marketing letters | ||
| 22.10. | Trump admin readies 'imminent' probe into other nations' drug pricing, raising new tariff threat: FT | ||
| 21.10. | Exit Axial, enter Vertero: Biotech rebrands, refocuses and raises $20M | ||
| 21.10. | Kenvue calls on FDA to reject proposed Tylenol safety warnings, pushes back on alleged autism link | ||
| 21.10. | Novo Nordisk telegraphs board shakeup, with former CEO Lars Soerensen tapped to chair | ||
| 21.10. | FDA expansion for Novo's Rybelsus is a new 'benchmark' for oral metabolism drugs | ||
| 21.10. | Wilmington PharmaTech, on mission to boost US drug ingredient capacity, snares investment from PE firm Curewell | ||
| 21.10. | India's ACG pumps $200M into its first US empty-capsule production facility | ||
| 20.10. | Merck grows more ambitious about 'workhorse' TROP2 ADC as partner Kelun posts phase 3 wins | ||
| 20.10. | How to invest in America? Vaccinate: BIO rolls out awareness campaign amid rising misinformation | ||
| 20.10. | TV drug ad spending sinks 19% in Q3 despite football season uptick in September | ||
| 20.10. | Roche's aging oncology blockbuster Gazyva snares FDA nod to move into lupus nephritis | ||
| 20.10. | Theravance stands up nOH physician education campaign ahead of pivotal data | ||
| 20.10. | Merck grows again in Va. with $3B small-molecule drug plant, 500+ potential hires | ||
| 17.10. | Merck KGaA's EMD Serono strikes MFN deal in Trump's fertility treatment pricing push | ||
| 17.10. | Sanofi gets one thumbs up, one thumbs down from Europe's CHMP | ||
| 17.10. | FDA names 9 first recipients of 1- to 2-month priority review vouchers | ||
| 16.10. | Genentech preps for flu season with DTC program offering discounted Xofluza | ||
| 16.10. | Merck's Keytruda follows primary endpoint win in ovarian cancer study with OS triumph | ||
| 16.10. | Novartis advances IgAN efforts with phase 3 win for Fabhalta, plots FDA filing for full approval | ||
| 15.10. | AstraZeneca to spend $445M to boost production of Lokelma at Texas plant | ||
| 15.10. | Real Chemistry, Publicis Health make moves to expand targeted marketing capabilities | ||
| 15.10. | GSK makes nice with antifungal partner Scynexis with $22M payment to resolve trial dispute |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .